# OnCo record chondrosarcoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/chondrosarcoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "chondrosarcoma" ;
  schema:name "Chondrosarcoma"@en ;
  schema:alternateName "Cartilage sarcoma"@en, "Atypical cartilaginous tumour (grade 1, limbs)"@en, "Dedifferentiated chondrosarcoma"@en, "Mesenchymal chondrosarcoma"@en ;
  schema:description "Chondrosarcoma is a cancer of cartilage-forming cells in bone. It is nearly immune to chemotherapy and radiotherapy, so complete surgery is the treatment, with proton or carbon-ion beams for skull base and spine tumours that cannot be fully removed. Half of conventional tumours carry an IDH mutation, and the IDH1 blocker ivosidenib is in a phase 3 trial."@en ;
  schema:url <https://onco.cc/cancers/chondrosarcoma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Chondrosarcoma> ;
  schema:citation <https://en.wikipedia.org/wiki/Chondrosarcoma> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/osteosarcoma/>, <https://onco.cc/cancers/chordoma/> ;
  onco:pipeline <https://onco.cc/drugs/ivosidenib/>, <https://onco.cc/trials/nct06127407/>, <https://onco.cc/technologies/idh-inhibitors/>, <https://onco.cc/technologies/carbon-ion/> ;
  onco:standardOfCare <https://onco.cc/technologies/limb-salvage-surgery/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/limb-salvage-surgery/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/carbon-ion/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/drugs/ivosidenib/>, <https://onco.cc/trials/nct06127407/>, <https://onco.cc/technologies/idh-inhibitors/> .